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bone repairSummary The research project entitled “rapid prototyping of custom-made bone-forming
tissue engineering constructs” (RAPIDOS) is one of the three unique projects that are the result
of the first coordinated call for research proposals in biomaterials launched by the European
Union Commission and the National Natural Science Foundation of China in 2013 for facilitating
bilateral translational research. We formed the RAPIDOS European and Chinese consortium
with the aim of applying technologies creating custom-made tissue engineered constructs
made of resorbable polymer and calcium phosphate ceramic composites specifically designed
by integrating the following: (1) imaging and information technologies, (2) biomaterials and
process engineering, and (3) biological and biomedical engineering for novel and truly transla-
tional bone repair solutions. Advanced solid free form fabrication technologies, precise stereo-
lithography, and low-temperature rapid prototyping provide the necessary control to create
innovative high-resolution medical implants. The use of Chinese medicine extracts, such as
the bone anabolic factor icaritin, which has been shown to promote osteogenic differentiation
of stem cells and enhance bone healing in vivo, is a safe and technologically relevant alterna-
tive to the intensely debated growth factors delivery strategies. This unique initiative driven
by a global consortium is expected to accelerate scientific progress in the important field of
biomaterials and to foster strong scientific cooperation between China and Europe.
Copyrightª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background on the European UnioneChina
joint project
The genesis
The launching of the biomaterials cocoordinated research
call by the European Commission and the National Natural
Science Foundation of China (NSFC) originated from the
undertakings of European and Chinese scientists repre-
sented by the European Society for Biomaterials
(2007e2013 president: Professor Luigi Ambrosio) and the
Chinese Committee for Biomaterials (president: Professor
Xingdong Zhang) together with the representatives of the
respective funding agencies. Following initiatives such as
the ChinaeEurope Symposiums on Biomaterials in Regen-
erative Medicine started in 2006, and held alternatively in
Europe and China promoting collaboration between Euro-
pean and Chinese researchers and fostering the exchange
of talent, trends in biomaterials research and applications
were identified [1,2]. This collective endeavour targeted
the enhancement of international collaboration in trans-
lational research and development where the needs to
develop innovative biomaterial products for clinical ap-
plications in a truly international effort are desirable in
order to reach the markets in a short to medium term
[3,4].
Among the research directions that were expected to
lead to consolidation and extension of the knowledge and
competitiveness of Europe and China in biomaterials in
regenerative medicine, rapid prototyping (RP) technology
for custom-made scaffolds was recognised for its strong
potential. This led to the first coordinated call for research
proposals in biomaterials by the European Commission and
the NSFC, launched in 2013 [5,6].The call
The proposed call from the European Union (EU) commis-
sion was entitled “Biomaterials: imaging and rapid precise
prototyping technology for custom made scaffolds” [7].
The expected impacts were targeting the development
of technologies for the production of custom-made struc-
tures for the repair or regeneration of human tissues, and
the improved manufacturing and performance of custom-
made scaffolds for tissue repair or regeneration in the
medium to long term. Additionally, a more robust Euro-
peaneChinese research cooperation as well as successful
joint research activities, publications, contributions to
scientific events, and more intensive exchange and training
of researchers were anticipated.
Formation of the RAPIDOS consortium
History of a successful application
The 9th World Biomaterials Congress organised in Chengdu,
China, during the summer of 2012, which attracted
biomaterial scientists from around the globe, was a catalyst
for the project genesis on biomaterialsdimaging and rapid
precise prototyping technology for custom-made
scaffoldsdas most of the partners to be were united in
this single location. Back from the world congregation, e-
mail exchanges and discussion between the initial groups
were started for the definition of an exciting research
project and integration of partners with complementary
expertise (Fig. 1). The proposals were submitted in October
2012 to the European Commission and the NSFC. The
project was positively evaluated in February 2013 and
effectively started on 1 July 2013 for both Chinese and
Figure 1 Structure and interactions of the RAPIDOS con-
sortium and partners’ expertise. AOF Z AO Forschungs Insti-
tute Davos (Switzerland); PLA 301 Z General Hospital of
People’s Liberation ArmyeBeijing 301 Hospital (People’s Re-
public of China); QMUL Z Queen Mary, University of London
(United Kingdom); RAPIDOS Z rapid prototyping of custom-
made bone-forming tissue engineering constructs; SIAT Z
Shenzhen Institutes of Advanced Technology, Chinese Academy
of Sciences (People’s Republic of China); SJUTZ Shanghai Jiao
Tong University (People’s Republic of China); UT Z University
of Twente (The Netherlands); Xpand Z Xpand Biotechnology
B.V. (The Netherlands).
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call.
RAPIDOS project structure and management
The project consortium is an integrated collaborative
project involving four partners from three EU countries
together with three Chinese partners from different loca-
tions in a multidisciplinary collaboration. The strength of
this team relies on its composition: a translational research
institute with a strong track record, three academic uni-
versities, a clinic, and a small- and medium-sized enter-
prise and their integrated capability, which encompass the
whole spectrum of biomaterials and bioengineering disci-
plines. The focus on relevant clinical problems (blow-out
fracture of the walls of the orbit for EU partners and long
bone defect for Chinese partners) will ensure the long-term
success of our custom-made tissue engineered approach.
Thus, this consortium is aiming to establish a benchmark in
the development and transfer of innovative and
performance-orientated biomaterials RP at an international
scale.
Additionally, an information technology platform has
been created comprising a portal linking the EUeCN part-
ners, the partners with the AO Foundation orthopaedic
surgeons network (more than 10,000 surgeons worldwide),
the biomaterials and tissue engineering (TE) scientific
community, and the lay community [8].Scientific scope of the RAPIDOS project
Bone is a biological tissue with a robust capacity to heal and
regenerate. Indeed, most bone fractures will, whenappropriately treated, heal without any complication.
However, there are still numbers of cases when the current
surgical techniques together with bone grafts such as the
autologous bone gold standard graft are insufficient. Ex-
amples of such impaired bone regeneration are large
trauma with infections (e.g., road accidents) and bone
metabolic disorders including avascular necrosis [9,10]. In
March 2010, the United Nations General Assembly pro-
claimed the period 2011e2020 as the Decade of Action for
Road Safety [11]. Road traffic injuries kill nearly 1.3 million
people annually. If current trends continue, road crashes
are predicted to rise from ninth leading cause of death to
fifth by 2030. About 50 million individuals sustain nonfatal
injuries that represent an important cause of disability
worldwide. Road traffic injuries are the leading cause of
death among young people, aged between 15 and 29. Until
recently, the extent of the road safety situation around the
world was unclear. In 2009, the World Health Organization
published the global status report on road safety as the first
assessment of the road safety situation at the global level.
Bone is the most often transplanted tissue after blood,
and the need for bone graft substitute materials is enor-
mous. Worldwide, the number of bone grafts used in sur-
gical procedures has been estimated at more than 24
million in 2010. About one-third represents the European
market, whereas the total Asian markets (China and India)
for bone graft substitutes and other biomaterials increased
by 53.2% from 2009 to 2010. The bone graft sales are
forecasted to reach a total of $3.3 billion worldwide in 2017
[12]. Therefore, the global increase of needs for bone graft
substitutes and emergence of large healthcare providers in
Asia support the necessities for better bone repair solutions
based on biomaterial scaffolds.
Among the pertinent nonhealing bone fractures, the
region of the head is a major target for development of
precise custom-made bone constructs. In craniomax-
illofacial surgery, large blow-out orbital floor fractures
have still mitigated outcomes, and improved scaffold so-
lutions are needed [13]. The reconstruction of large bone
defects in proximal femur or proximal tibia in orthopaedic
trauma surgery is also an enormous challenge for bioma-
terial devices owing to the requirements for both complex
shape and partial load-bearing ability, but also because of
the risk of incidence of steroid-associated osteonecrosis or
infection, which may exceed 30% for large open fractures
[14].
Biomaterials and bone Tissue Engineering (TE) have
failed until now in facilitating reliable bone repair [15]. The
technical issues for the engineering of a scaffold for bone
TE are as follows: (1) fabrication of biomaterial scaffolds
with anatomical fit of complex three-dimensional (3D) large
bone defects; (2) fabrication of biomaterials with adequate
mechanical and structural stability/degradation kinetics;
(3) controlling the behaviour (adhesion, proliferation, dif-
ferentiation, and matrix remodelling) of cells and tissues at
the interface with biomaterials; and (4) fabrication of
biomaterials with optimised macroarchitecture for
improved mass transport and perfusion for delivery of bio-
logical effectors. These effectors could be antibacterial
agents [e.g., magnesium (Mg)] compounded with the bio-
materials to decrease infection in large trauma due to road
traffic accidents, growth factors, nutrients, or other cells.
Rapid prototyping of tissue engineering constructs 81However, the main desirable biological capacities of a
biomaterial scaffold for bone are osteoconductivity,
osteoinductivity, and osteogenicity. Calcium phosphate
(CaP) ceramics and incorporated growth factors can pro-
vide these properties [16,17]. The use and efficacy of
growth factor containing bone graft substitutes (e.g.,
Infuse; recombinant bone human bone morphogenetic
protein-2 or rhBMP-2) is intensely debated nowadays [18],
and use of Chinese medicine extracts such as the bone
anabolic compound icaritin, which has been shown to pro-
mote osteogenic differentiation of stem cells and enhance
bone healing in vivo, is a promising alternative [19,20].
For bone repair, patient-specific tissue engineered bio-
materials can address several drawbacks of the current
orthopaedic devices: optimised shape for best cosmetic,
mechanical and anatomical stability, no thermosensitivity
associated with the use of metallic implants, optimised
internal architecture in accordance to the delivered bio-
logical effectors (e.g., cells, antibacterial agent, Chinese
medicine extract, magnesium), and mass transport for
vascularisation and bone ingrowth. However, there are also
other clinical considerations to be taken into account.
Definitely, a macroscopic precision above 0.5 mm for the
considered biomaterial scaffolds is unnecessary for bone
repair as surgeons would not be able to achieve construct
positioning with a better accuracy in challenging surgical
situations [21]. Additionally, clinical available 3D imaging
instruments [e.g., computed tomography (CT)] have a
precision not lower than 0.2 mm, and sometimes precision
less than 0.4 mm can be achieved, like in the orbit. Hence,
the clinical focus is necessary to achieve real and relevant
progresses toward fitting custom-made biomaterial
products.
A high resolution for scaffold TE is needed to create
biomaterial scaffolds with correct external shape,
adequate mechanical and resorption properties, and opti-
mised internal architecture and biofunctionalities in com-
bination with a clinically relevant cell source: human
mesenchymal stromal cells (hMSCs) in the case of this
consortium. Advanced solid free form fabrication, also
called rapid prototyping, could provide the necessary con-
trol to create such innovative medical devices. Stereo-
lithography (SLA) offers the high resolution necessary to
create controlled architecture and anatomically well-fitting
devices. The low-temperature rapid prototyping (LT-RP) is
a unique technique in its ability to incorporate
temperature-sensitive active compounds into the scaffolds
[19,22,23].
Thus, the goal of this European and Chinese consortium
is to apply RP technologies to create custom-made tissue
engineered biomaterial constructs by integrating (1) imag-
ing and information technologies, (2) biomaterials and
process engineering, and (3) biological and biomedical en-
gineering for novel and truly translational bone repair so-
lutions [24].
There are major challenges to our approaches [25].
First, we need to integrate patient-specific clinical images
together with relevant architecture design for optimal mass
transport and delivery of biological stimuli (hMSCs and
icaritin) and develop a valid surgical procedure. Second, we
need to develop adequate biomaterial composites with
controlled nanostructure and precise scaffold fabricationtechniques. Third, it is necessary to create adaptive and
biologically active TE constructs through the addition of
osteogenic biological stimuli such as hMSCs isolated from
the patient bone marrow (endogenous growth factor) and/
or small anabolic molecule extract from Chinese medicine
(e.g., icaritin). Finally, we need to combine all of the above
advanced stages for the delivery and possibly product
registration of the custom-made biomaterial tissue-
engineered construct.
Concept and objectives of the RAPIDOS project
Imaging custom-made scaffold design
Image processing software and computer graphic technol-
ogies can now be semiautomated to provide radiologists
and surgeons with tools to analyse clinical imaging data
such as CT images and exploit this original dataset to
create, for example, a 3D stereolithographic model of an
implant that can be transferred as a set of coordinates for
the printing system to create a custom-made scaffold
implant (Fig. 2). In this consortium, we will develop a
computer workflow based on clinical CT data in which it is
envisioned that the surgeons will have an interactive tool to
decide which scaffold implant design is suitable for the
reconstruction of the bony defect with taking into account
boundaries such as the biomaterials’ mechanical properties
and fabrication parameters.
Biomaterials
A poly(trimethylene carbonate) (PTMC)-based resin will be
used in combination with osteoinductive CaP [i.e., biphasic
calcium phosphate (BCP)] particles for the preparation of
the SLA scaffold. PTMC resins can be prepared and photo-
crosslinked to form a solid material [26,27]. PTMC is an
amorphous polymer with a relatively low elastic modulus of
5e7 MPa at room temperature. PTMC degrades enzymati-
cally in vivo via a surface erosion process without the for-
mation of acidic degradation products [28,29]. The polymer
has not been shown to calcify or lead to the formation of
new bone upon implantation. However, its combination
with BCP provides osteoinductive properties to the scaffold
as the blended BCP becomes exposed upon in vivo degra-
dation of the PTMC matrix. Moreover, the combination of
bone anabolic icaritin loaded polymeric microspheres or
nanofibres prepared from poly(lactic acid) (PLA) or poly(-
lactic-co-glycolic acid) (PLGA) within the PTMC resin will
provide additional biofunctionality to the scaffold through
the sustained release of the Chinese medicine extract
provided by the Chinese partners [30,31]. In addition, such
polyester fibres will strengthen the mechanical properties
of the resulting polymerepolymer composites, owing to the
high modulus of PLA and derivatives. The nanofibres will
also provide a simple mean to texture the interface of the
composites, which is a well-established factor impacting on
cell adhesion and bone engineering [32,33]. PLGA/CaP
composites will be the alternative biomaterial compositions
for the direct comparison of several RP technologies. PLGA
and CaP [i.e., tricalcium phosphate (TCP)] particles will be
combined to form osteoinductive scaffolds. PLGA is
Figure 2 Scheme of the RAPIDOS approach toward custom-
made scaffolds: from standard clinical computed tomography
data collection and processing to create specific implant design
to development of composite biomaterials for fabrication of
implants using additive manufacturing technologies and inclu-
sion of bioactive products. CaPZ calcium phosphate particles;
HAACZ hydroxypropyltrimethyl ammonium chloride chitosan;
Mg Z magnesium; PLGA Z poly(L-lactide-co-glycolide);
PTMC Z poly(trimethyl carbonate); RAPIDOS Z rapid proto-
typing of custom-made bone-forming tissue engineering con-
structs; TCP Z b-tricalcium phosphate.
82 D. Eglin et al.biocompatible and possesses a range of degradation rates
that can be adjusted to the new bone tissue growth rate,
which results in a natural replacement of tissue without the
long-term complications associated with none or very slow
resorbable implants [34,35]. However, some drawbacks still
exist in its applications, including notably the generation of
acidic species, resulting in a decrease in local pH, as it
could cause tissue inflammation in the region adjacent to
the implants [36]. To overcome these drawbacks, pH neu-
tralisation with basic compounds such as TCP and other
biodegradable and bioactive ceramics has been shown to
improve the dissolution properties (neutral pH upon
degradation of PLGA) and enhance cell adhesion and bone
formation [37,38]. TCP is used commercially in clinical or-
thopaedics as material for bone fillers, and as a local de-
livery system for drug and cells [39]. PLGA/TCP scaffolds
prepared using LT-RP as a TE construct and drug release
device have already been reported [40]. The different
degradation mechanisms of PLGA and PTMC will influence
the availability of the biological stimuli (e.g., icaritin,
magnesium) included in the bulk of the composite matrices
of the scaffolds allowing for improved release and activity
of the biologics [41e46] and provide a simple tool to control
the remodelling of the matrix and its mechanical behaviour.
Furthermore, Chinese partners have synthesised a newquaternised chitosan derivative [hydroxypropyltrimethyl
ammonium chloride chitosan (HACC)] that contains a series
of substitution of quaternary ammonium, and demon-
strated that HACC with 26% degree of substitution had a
strong antibacterial activity and simultaneously good
cytocompatibility with osteogenic cells [47]. An additional
strategy of the consortium will be to impregnate the chi-
tosan derivatives into the PLGA/TCP and PTMC/CaP com-
posites, which would provide dual functions to promote
bone regeneration as well as prevent bacterial
colonization.
RP technologies
In our consortium, high-resolution SLA will be used and
developed by the EU partners (Fig. 2). It is a precise RP
manufacturing method, in which objects are constructed in
a layer-by-layer fashion by photopolymerisation [48]. By
using SLA to directly prepare the TE scaffolds, the draw-
backs of conventional scaffold preparation methods can be
overcome: cell support structures with predetermined ar-
chitectures can be prepared that not only precisely fit a
(bone) defect, but also create accurate macrostructures
down to a cell size (w20 mm) [49]. It has already been
shown that scaffolds prepared via SLA fabrication can have
adaptable mechanical stiffness and permeability that, in
turn, can stimulate mesenchymal stromal cell (MSC) re-
sponses and potentially promote faster bone tissue regen-
eration [50]. LT-RP technology will be used and developed
to yield biological effectors (e.g., cells, antibacterial
agent, Chinese medicine extract, magnesium) incorporated
into PLGA/TCP scaffolds by the Chinese partners (Fig. 2)
[51]. PTMC/CaP composites prepared by LT-RP with a
different degradation profile compared to PLGA/CaP will
be prepared for direct comparison to the planned European
study using SLA fabrication [52].
Tissue engineering for bone repair
This consortium aims to modulate and control the biological
response of hMSCs seeded into scaffolds via (1) the opti-
misation of the scaffold architecture and (2) bio-
functionality (icaritin and Mg-loaded microspheres and
particles). The anti-infection and antibacterial effects of
PLGA/TCP/Mg and HACC incorporated into PLGA/TCP
scaffolds will also be investigated. This specific objective
will be coordinated with the Chinese partners to develop
common experimental protocols in order to standardise the
evaluation of the biological performance of the prepared
TE constructs. Typically, MSC seeding efficiency, prolifera-
tion, alkaline phosphatase activity, osteogenic differentia-
tion, calcium deposition in several scaffold architectures,
PTMC/CaP (and PLGA/TCP) compositions and in the pres-
ence of icaritin and Mg-loaded microparticles at different
concentrations will be assessed. The final goal will be the
selection of scaffold characteristics (e.g., porosity, pore
size and design, mechanics) that allow for improved cell
response. Then, the in vivo assessment of the selected
candidate custom-made bone TE construct(s) will be per-
formed in a relevant preclinical model in parallel by the
European and Chinese partners.
Rapid prototyping of tissue engineering constructs 83In vivo efficacy investigation will be designed to eval-
uate osteogenesis, for example, in a bilateral ulna bone
segmental defect model implanted with composite scaffold
in rabbits, with radiography and in vivo micro-CT for
studying new bone regeneration and histology for host tis-
sue and scaffold material interactions. Finally, a large an-
imal pilot study has been performed to assess the whole
chain of concepts from imaging to bone TE in order to
demonstrate clinical feasibility of the custom-made
biomaterial scaffold-based therapy prior to clinical testing.
Impact and perspectives on the RAPIDOS
project
To date, a clinical CT imaging process technology workflow
for the development of anatomically relevant and precise
custom-made macrostructured designed scaffolds has been
created. The goal of this workflow is to allow the surgeons
to design and self-assess patient-specific implants taking
into account the constraints of the biomaterial and fabri-
cation process. The optimisation of composite for-
mulationsdpoly(trimethylcarbonate)/CaP and PLGA/TCP/
Mg for SLA and low-temperature rapid manufacturing,
respectivelydis well advanced, and already composite
scaffolds can be fabricated via both SLA and LT-RP. PLA
nanofibres loaded with icaritin have been prepared for
incorporation into the photopolymerisable resin formula-
tion for SLA. In vitro and in vivo studies have shown the
osteopromotive effect of icaritin loaded into scaffolds, and
magnesium was shown to influence biofilm formation onto
the surface of PLGA/TCP/Mg scaffolds. We expect the
combined approach of the project to give rise to additional
and multiple innovations to be exploited by the networks of
partners.
Finally, we hope that through our (EUeChina) collabo-
ration, we can advance therapeutic solutions to ease
suffering from nonhealing bone fractures/defects in the
future and help achieve faster patient recovery through the
development of custom-made implant and patient-specific
therapy.
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